Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Non-Current Assets: 2019-2025

Historic Non-Current Assets for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $32.5 million.

  • Eton Pharmaceuticals' Non-Current Assets rose 433.65% to $32.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.5 million, marking a year-over-year increase of 433.65%. This contributed to the annual value of $35.1 million for FY2024, which is 616.22% up from last year.
  • Eton Pharmaceuticals' Non-Current Assets amounted to $32.5 million in Q3 2025, which was down 2.18% from $33.2 million recorded in Q2 2025.
  • Eton Pharmaceuticals' Non-Current Assets' 5-year high stood at $35.1 million during Q4 2024, with a 5-year trough of $743,000 in Q3 2021.
  • For the 3-year period, Eton Pharmaceuticals' Non-Current Assets averaged around $15.7 million, with its median value being $6.4 million (2024).
  • Its Non-Current Assets has fluctuated over the past 5 years, first plummeted by 53.85% in 2021, then soared by 616.22% in 2024.
  • Over the past 5 years, Eton Pharmaceuticals' Non-Current Assets (Quarterly) stood at $3.9 million in 2021, then skyrocketed by 30.17% to $5.0 million in 2022, then fell by 2.49% to $4.9 million in 2023, then soared by 616.22% to $35.1 million in 2024, then spiked by 433.65% to $32.5 million in 2025.
  • Its last three reported values are $32.5 million in Q3 2025, $33.2 million for Q2 2025, and $34.1 million during Q1 2025.